Resuscitation · 2020 · 46 citations · 31 references
PharmacyCardiologyPharmacoeconomicsCost-effectiveness AnalysisHealth EconomicsResuscitationCardiac Arrest ManagementCardiopulmonary ResuscitationCost-effectiveness ModelingExtracorporeal Life SupportHealthcare Cost AnalysisModel-based Economic EvaluationCardiopulmonary ArrestCost-effectivenessEconomic Evaluation AppraisalIncremental Cost EstimationLong-term Cost-effectiveness ModelingOut-of-hospital Cardiac ArrestPulseless Ventricular TachycardiaQuality-adjusted Life Year Modeling
AIM: Extracorporeal cardiopulmonary resuscitation (ECPR) is an evolving resuscitative method for refractory cardiopulmonary arrests. However, considering the substantial healthcare costs and resources involved, there is an urgent need for a full economic evaluation. We therefore assessed the cost-effectiveness of ECPR for refractory ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT). METHODS: We developed a decision model to estimate lifetime costs and outcomes for out-of-hospital cardiac arrest patients with VF/pVT who received either ECPR or conventional cardiopulmonary resuscitation. Quality-adjusted life-years (QALY) was used as the main outcome measure. This model was a combination of a decision tree model for the acute phase based on a prospective observational study (SAVE-J study), together with a Markov model for long-term follow-up periods extrapolated from published data. To evaluate the robustness of this model, we conducted a comprehensive deterministic sensitivity analysis (DSA) and a probabilistic sensitivity analysis (PSA). RESULTS: ECPR was cost-effective, with an incremental cost of ¥3,521,189 (Є30,227), an incremental effectiveness of 1.34 QALY, and an incremental cost-effectiveness ratio of ¥2,619,692 (Є22,489) per QALY gained. DSA revealed that the present model was most sensitive to probability of Cerebral Performance Category 1 after ECPR (¥2,153,977/QALY to ¥3,186,475/QALY), patient age (¥2,170,112/QALY to ¥3,334,252/QALY), and long-term medical cost for modified Rankin Scale 0 (¥2,280,352/QALY to ¥2,855,330/QALY). PSA indicated ECPR to be cost-effective and below the willingness-to-pay threshold of ¥5,000,000 with an 86.7 % possibility. CONCLUSIONS: ECPR was an economically acceptable resuscitative strategy, and the results of the present study were robust even when considering the uncertainty of all parameters.
31
Interobserver agreement for the assessment of handicap in stroke patients.
John C. van Swieten, Peter J. Koudstaal, Marieke C. Visser et al. · Stroke · 1988 · 6.5K citations · Full text
Life Sciences, Neurology, Functional Movement Assessment +14
Giles J. Peek, Miranda Mugford, Ravindranath Tiruvoipati et al. · The Lancet · 2009 · 3.4K citations
Medicine, Respiratory Therapy, Cost-effectiveness Analysis +11
Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports
Ian Jacobs, Vinay Nadkarni, Jan Bahr et al. · Circulation · 2004 · 2.6K citations · Full text
Health Professions, Emergency Medicine, Critical Care Medicine +10
Don Husereau, Michael Drummond, Stavros Petrou et al. · Value in Health · 2013 · 2.1K citations · Full text
European Resuscitation Council Guidelines for Resuscitation 2015
Jasmeet Soar, Jerry P. Nolan, Bernd W. Böttiger et al. · Resuscitation · 2015 · 1.5K citations · Full text
Health Professions, Emergency Medical Services, Emergency Medicine +12